Nobixal (Tianeptine Sodium)

Tianeptine Sodium, the active ingredient in Nobixal, is an atypical antidepressant presented as an oral formulation for systemic use. It is indicated for the treatment of major depressive disorder in adult patients and works by modulating serotonergic and glutamatergic pathways.

GNH USA supplies Nobixal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for importers. It offers batch‑specific certificates of analysis and supports cold‑chain logistics where required.

Nobixal is an atypical antidepressant used within the depressive disorder therapeutic area.

Major depressive disorder: reduces core depressive symptoms and improves functional capacity in adults. Depressive episodes associated with major depressive disorder: helps alleviate mood disturbances during acute phases. Recurrent major depressive disorder: supports maintenance of remission and reduces relapse risk.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient tension‑type headaches. - Dizziness: occasional light‑headedness. - Dry mouth: reduced salivation. - Constipation: slowed bowel movements. - Insomnia: difficulty initiating sleep.

Serious or Rare Side Effects: - Suicidal ideation: emergence or worsening of suicidal thoughts. - Severe liver injury: elevated transaminases or hepatic failure. - Pancreatitis: acute abdominal pain with elevated enzymes. - Anaphylactic reaction: rapid onset of swelling, rash, and respiratory distress. - Seizures: convulsive episodes, particularly in predisposed individuals.

Before initiating therapy, consider the following precautions: - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown excretion in milk; caution advised. - Renal impairment: adjust use and monitor renal function. - History of seizures: monitor closely for neurological events. - Concomitant MAO inhibitors: avoid due to potential serotonin‑related toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Tianeptine Sodium may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin‑related effects. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., fluoxetine, erythromycin): may increase plasma levels. - Antihypertensives: possible additive hypotensive effect. - Antidiabetic drugs: monitor glucose control. - Other antidepressants: assess for overlapping side‑effect profiles. - NSAIDs: increased risk of gastrointestinal bleeding.